Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis

Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis could describe disease progression in a placebo‐treated p...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2015-09, Vol.4 (9), p.516-526
Main Authors: Berkhout, J, Stone, JA, Verhamme, KM, Stricker, BH, Sturkenboom, MC, Danhof, M, Post, TM
Format: Article
Language:English
Subjects:
Biomarkers
Clinical trials
Fractures
Homeostasis
Menopause
Original
Osteoporosis
Pharmacology
Physiology
Population
Systems analysis
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303
cites cdi_FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303
container_end_page 526
container_issue 9
container_start_page 516
container_title CPT: pharmacometrics and systems pharmacology
container_volume 4
creator Berkhout, J
Stone, JA
Verhamme, KM
Stricker, BH
Sturkenboom, MC
Danhof, M
Post, TM
description Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis could describe disease progression in a placebo‐treated population from the Early Postmenopausal Intervention Cohort (EPIC) study. First, we qualified the model using a subset from the placebo arm of the EPIC study of 222 women who had similar demographic characteristics as the 149 women from the placebo arm of the original population. Second, we applied the model to all 470 women. Bone mineral density (BMD) dynamics were changed to an indirect response model to describe lumbar spine and total hip BMD in this second population. This updated disease systems analysis placebo model describes the dynamics of all biomarkers in the corresponding datasets to a very good approximation; a good description of an individual placebo response will be valuable for evaluating treatments for osteoporosis.
doi_str_mv 10.1002/psp4.12006
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4592531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1721353736</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhyMEolXphQdAlrggpC3-Fyd7QdoWKJUWNVLL2Zp1JttUTibECSic4A14xj4J3qZUhQO-2LK_-TyaX5I8F_xIcC7fdKHTR0Jybh4l-1IYtcgVN48fnPeSwxCueVyZ5mLJnyZ70uhUKCX2k5-rrvO1g6GmllHFgF1MYcAmsOIK-gYcedpONz9-HUPAkhUeHG6IFdSNfi76RCV6NhBbteCn78jW1G5jwSX2DXsHA-y0BYWhwZY6GAN4dh6_oI56CnV4ljypwAc8vNsPks8f3l-efFysz0_PTlbrhUtFbhaVQ-nSiovSYKagyjVwvclLVC4tIeOpBieVUyAytSmFFjkaE69NpbmrFFcHydvZ242bBkuH7dCDt11fN9BPlqC2f7-09ZXd0ler06VMlYiCV3eCnr6MGAbb1MGh99AijcGKTAqVqkyZiL78B72msY_zCVbKJVdKmjyN1OuZcnEQocfqvhnB7S5cuwvX3oYb4RcP279H_0QZATED32qP039Utrgo9Cz9DYonss4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290332685</pqid></control><display><type>article</type><title>Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><creator>Berkhout, J ; Stone, JA ; Verhamme, KM ; Stricker, BH ; Sturkenboom, MC ; Danhof, M ; Post, TM</creator><creatorcontrib>Berkhout, J ; Stone, JA ; Verhamme, KM ; Stricker, BH ; Sturkenboom, MC ; Danhof, M ; Post, TM</creatorcontrib><description>Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis could describe disease progression in a placebo‐treated population from the Early Postmenopausal Intervention Cohort (EPIC) study. First, we qualified the model using a subset from the placebo arm of the EPIC study of 222 women who had similar demographic characteristics as the 149 women from the placebo arm of the original population. Second, we applied the model to all 470 women. Bone mineral density (BMD) dynamics were changed to an indirect response model to describe lumbar spine and total hip BMD in this second population. This updated disease systems analysis placebo model describes the dynamics of all biomarkers in the corresponding datasets to a very good approximation; a good description of an individual placebo response will be valuable for evaluating treatments for osteoporosis.</description><identifier>ISSN: 2163-8306</identifier><identifier>EISSN: 2163-8306</identifier><identifier>DOI: 10.1002/psp4.12006</identifier><identifier>PMID: 26451331</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Biomarkers ; Clinical trials ; Fractures ; Homeostasis ; Menopause ; Original ; Osteoporosis ; Pharmacology ; Physiology ; Population ; Systems analysis ; Womens health</subject><ispartof>CPT: pharmacometrics and systems pharmacology, 2015-09, Vol.4 (9), p.516-526</ispartof><rights>2015 The Authors CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2015. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 The Authors CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303</citedby><cites>FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290332685/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290332685?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26451331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berkhout, J</creatorcontrib><creatorcontrib>Stone, JA</creatorcontrib><creatorcontrib>Verhamme, KM</creatorcontrib><creatorcontrib>Stricker, BH</creatorcontrib><creatorcontrib>Sturkenboom, MC</creatorcontrib><creatorcontrib>Danhof, M</creatorcontrib><creatorcontrib>Post, TM</creatorcontrib><title>Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis</title><title>CPT: pharmacometrics and systems pharmacology</title><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><description>Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis could describe disease progression in a placebo‐treated population from the Early Postmenopausal Intervention Cohort (EPIC) study. First, we qualified the model using a subset from the placebo arm of the EPIC study of 222 women who had similar demographic characteristics as the 149 women from the placebo arm of the original population. Second, we applied the model to all 470 women. Bone mineral density (BMD) dynamics were changed to an indirect response model to describe lumbar spine and total hip BMD in this second population. This updated disease systems analysis placebo model describes the dynamics of all biomarkers in the corresponding datasets to a very good approximation; a good description of an individual placebo response will be valuable for evaluating treatments for osteoporosis.</description><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Fractures</subject><subject>Homeostasis</subject><subject>Menopause</subject><subject>Original</subject><subject>Osteoporosis</subject><subject>Pharmacology</subject><subject>Physiology</subject><subject>Population</subject><subject>Systems analysis</subject><subject>Womens health</subject><issn>2163-8306</issn><issn>2163-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kc9u1DAQhyMEolXphQdAlrggpC3-Fyd7QdoWKJUWNVLL2Zp1JttUTibECSic4A14xj4J3qZUhQO-2LK_-TyaX5I8F_xIcC7fdKHTR0Jybh4l-1IYtcgVN48fnPeSwxCueVyZ5mLJnyZ70uhUKCX2k5-rrvO1g6GmllHFgF1MYcAmsOIK-gYcedpONz9-HUPAkhUeHG6IFdSNfi76RCV6NhBbteCn78jW1G5jwSX2DXsHA-y0BYWhwZY6GAN4dh6_oI56CnV4ljypwAc8vNsPks8f3l-efFysz0_PTlbrhUtFbhaVQ-nSiovSYKagyjVwvclLVC4tIeOpBieVUyAytSmFFjkaE69NpbmrFFcHydvZ242bBkuH7dCDt11fN9BPlqC2f7-09ZXd0ler06VMlYiCV3eCnr6MGAbb1MGh99AijcGKTAqVqkyZiL78B72msY_zCVbKJVdKmjyN1OuZcnEQocfqvhnB7S5cuwvX3oYb4RcP279H_0QZATED32qP039Utrgo9Cz9DYonss4</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Berkhout, J</creator><creator>Stone, JA</creator><creator>Verhamme, KM</creator><creator>Stricker, BH</creator><creator>Sturkenboom, MC</creator><creator>Danhof, M</creator><creator>Post, TM</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley &amp; Sons, Ltd</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201509</creationdate><title>Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis</title><author>Berkhout, J ; Stone, JA ; Verhamme, KM ; Stricker, BH ; Sturkenboom, MC ; Danhof, M ; Post, TM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Fractures</topic><topic>Homeostasis</topic><topic>Menopause</topic><topic>Original</topic><topic>Osteoporosis</topic><topic>Pharmacology</topic><topic>Physiology</topic><topic>Population</topic><topic>Systems analysis</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berkhout, J</creatorcontrib><creatorcontrib>Stone, JA</creatorcontrib><creatorcontrib>Verhamme, KM</creatorcontrib><creatorcontrib>Stricker, BH</creatorcontrib><creatorcontrib>Sturkenboom, MC</creatorcontrib><creatorcontrib>Danhof, M</creatorcontrib><creatorcontrib>Post, TM</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berkhout, J</au><au>Stone, JA</au><au>Verhamme, KM</au><au>Stricker, BH</au><au>Sturkenboom, MC</au><au>Danhof, M</au><au>Post, TM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis</atitle><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><date>2015-09</date><risdate>2015</risdate><volume>4</volume><issue>9</issue><spage>516</spage><epage>526</epage><pages>516-526</pages><issn>2163-8306</issn><eissn>2163-8306</eissn><abstract>Osteoporosis is a progressive bone disease characterized by decreased bone mass resulting in increased fracture risk. The objective of this investigation was to test whether a recently developed disease systems analysis model for osteoporosis could describe disease progression in a placebo‐treated population from the Early Postmenopausal Intervention Cohort (EPIC) study. First, we qualified the model using a subset from the placebo arm of the EPIC study of 222 women who had similar demographic characteristics as the 149 women from the placebo arm of the original population. Second, we applied the model to all 470 women. Bone mineral density (BMD) dynamics were changed to an indirect response model to describe lumbar spine and total hip BMD in this second population. This updated disease systems analysis placebo model describes the dynamics of all biomarkers in the corresponding datasets to a very good approximation; a good description of an individual placebo response will be valuable for evaluating treatments for osteoporosis.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>26451331</pmid><doi>10.1002/psp4.12006</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2163-8306
ispartof CPT: pharmacometrics and systems pharmacology, 2015-09, Vol.4 (9), p.516-526
issn 2163-8306
2163-8306
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4592531
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Wiley Online Library Open Access; PubMed Central
subjects Biomarkers
Clinical trials
Fractures
Homeostasis
Menopause
Original
Osteoporosis
Pharmacology
Physiology
Population
Systems analysis
Womens health
title Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T17%3A48%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20a%20Systems%20Pharmacology%E2%80%90Based%20Placebo%20Population%20Model%20to%20Analyze%20Long%E2%80%90Term%20Data%20of%20Postmenopausal%20Osteoporosis&rft.jtitle=CPT:%20pharmacometrics%20and%20systems%20pharmacology&rft.au=Berkhout,%20J&rft.date=2015-09&rft.volume=4&rft.issue=9&rft.spage=516&rft.epage=526&rft.pages=516-526&rft.issn=2163-8306&rft.eissn=2163-8306&rft_id=info:doi/10.1002/psp4.12006&rft_dat=%3Cproquest_pubme%3E1721353736%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5186-fce2c5f01d6e73af84a04b8de3c5da7054ac23c3a173bd1418e667056f40cf303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290332685&rft_id=info:pmid/26451331&rfr_iscdi=true